Vasopressin Tannate
Vasopressin tannate is a prolonged-acting repository form of vasopressin combined with tannic acid, designed for intramuscular injection to provide slow release of vasopressin for the treatment of central diabetes insipidus. The tannate salt creates a depot formulation that extends the duration of antidiuretic activity compared to aqueous vasopressin, allowing less frequent dosing. It has been largely replaced by the synthetic vasopressin analog desmopressin (DDAVP).
分子量
2785.4000 g/mol
TPSA
1290.00 Ų
Pharmacokinetics (PK)
Pharmacodynamics (PD)
SMILES
C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N.C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O
InChI
InChI=1S/C76H52O46.C46H65N15O12S2/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26;47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-20,52,63-65,76-101H,21H2;1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t52-,63-,64+,65-,76+;27-,28-,29-,30-,31-,32-,33-,34-/m10/s1
Molecular Formula
C122H117N15O58S2
HBD / HBA
39 / 62
回転可能結合数
50
重原子数
197
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Vasopressin tannate is a prolonged-acting repository form of vasopressin combined with tannic acid, designed for intramuscular injection to provide slow release of vasopressin for the treatment of central diabetes insipidus. The tannate salt creates a depot formulation that extends the duration of antidiuretic activity compared to aqueous vasopressin, allowing less frequent dosing. It has been largely replaced by the synthetic vasopressin analog desmopressin (DDAVP).
Yes, Vasopressin Tannate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201528. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 165411857. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vasopressin-tannate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vasopressin-tannate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vasopressin-tannate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vasopressin-tannate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vasopressin-tannate"></drugfyi-drug>